AKRX - Akorn, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
19.38
+0.05 (+0.26%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close19.33
Open19.21
Bid18.01 x 400
Ask19.50 x 100
Day's Range18.96 - 19.38
52 Week Range16.79 - 34.00
Volume1,081,727
Avg. Volume2,061,162
Market Cap2.428B
Beta1.66
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1991-05-24
1y Target EstN/A
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markit7 days ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 2. Over the last one-month, outflows of investor capital in ETFs holding AKRX totaled $850 million.

  • Reuters24 days ago

    Fresenius spokesman says probe into target Akorn continues

    Fresenius said on Tuesday its investigation into potential breaches of U.S. Food and Drug Administration data requirements at takeover target Akorn was ongoing. A Fresenius spokesman said that a legal ...

  • Reuters24 days ago

    UPDATE 1-Akorn settles U.S. SEC claims stemming from financial restatement

    Akorn Inc and two former executives have agreed to settle claims stemming from inaccurate financial statements the generic drugmaker issued in 2014 that it later needed to restate, the U.S. Securities and Exchange Commission on Monday said. Akorn, former Chief Financial Officer Timothy Dick and former Controller David Hebeda agreed to settle a lawsuit filed in federal court in Chicago. Dick and Hebeda each agreed to pay a $20,000 penalty, the SEC said.

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Akorn Inc.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 2. Index (PMI) data, output in the Healthcare sector is rising.

  • Investopedia2 months ago

    Top 3 Companies Owned by Valeant

    Learn more about Valeant Pharmaceuticals International Inc. and three of the top companies that Valeant owns or operates as subsidiaries.

  • The Wall Street Journal2 months ago

    [$$] How Missed Red Flags Derailed Drug Deal

    Akorn's checkered history should have given Fresenius pause before it agreed to buy the generic-drug company.

  • What You Must Know About Akorn Inc’s (NASDAQ:AKRX) Return on Equity
    Simply Wall St.2 months ago

    What You Must Know About Akorn Inc’s (NASDAQ:AKRX) Return on Equity

    Akorn Inc (NASDAQ:AKRX) generated a below-average return on equity of 8.24% in the past 12 months, while its industry returned 10.88%. Though AKRX’s recent performance is underwhelming, it is usefulRead More...

  • Here's Why Akorn, Inc. Stock Is Getting Thrashed Today
    Motley Fool2 months ago

    Here's Why Akorn, Inc. Stock Is Getting Thrashed Today

    An issue with "data integrity" could derail a planned acquisition of the generic drugmaker.

  • TheStreet.com2 months ago

    Akorn Shares Crash 34% After Fresenius Warns on Takeover Amid Data Breach Probe

    Germany's Fresenius SE said a probe into alleged data breaches at Akorn could scupper its planned $5 billion takeover of the Lake Forest, Ill.-based generic drugmaker.

  • TheStreet.com2 months ago

    Stock Futures Improve After Fed's Powell Repeats 'Gradual' Rate Hike Aim

    Global stocks were mixed in early Tuesday trading as investors sifted through prepared remarks ahead of the first of two appearances on Capitol Hill this week by new Fed chairman Jerome Powell.

  • MarketWatch2 months ago

    Akorn plunges 34% in premarket after Fresenius announces probe

    Shares of Akorn Inc. sank 34% in premarket trading on Tuesday, after German-based Fresenius SE said it was conducting a probe into possible data breaches at the U.S. generic-drugs manufacturer. The probe ...

  • Reuters2 months ago

    Fresenius may back out of Akorn deal if probe finds breaches

    Fresenius (FREG.DE) may back out of the planned acquisition of Akorn (AKRX.O) if its probe into data integrity at the U.S. maker of liquid generic drugs yields evidence of wrongdoing, the German healthcare group's chief executive said. "If the allegations prove to be conclusive and are so material that they would impact our targets, then we will withdraw from the contract," Stephan Sturm told a news conference on Tuesday. Fresenius had said late on Monday it was conducting an independent investigation into "alleged breaches" at Akorn of U.S. Food and Drug Administration data integrity requirements relating to product development.

  • Reuters2 months ago

    Fresenius may back out of Akorn deal if probe finds breaches

    Fresenius may back out of the planned acquisition of Akorn if its probe into data integrity at the U.S. maker of liquid generic drugs yields evidence of wrongdoing, the German healthcare group's chief ...

  • Reuters2 months ago

    Fresenius says probe may affect Akorn deal, sees slower 2018 sales

    German healthcare group Fresenius SE has raised doubts about its planned acquisition of Akorn because of a probe into data integrity at the U.S. maker of liquid generic drugs. Fresenius said it was conducting an independent investigation into "alleged breaches" at Akorn of U.S. Food and Drug Administration data integrity requirements relating to product development. "The Management and Supervisory Boards of Fresenius will assess the findings of that investigation," the company said in a statement late on Monday.

  • Reuters2 months ago

    Fresenius says probe may affect Akorn deal, sees slower 2018 sales

    German healthcare group Fresenius SE has raised doubts about its planned acquisition of Akorn because of a probe into data integrity at the U.S. maker of liquid generic drugs. Fresenius said it was conducting an independent investigation into "alleged breaches" at Akorn of U.S. Food and Drug Administration data integrity requirements relating to product development. "The Management and Supervisory Boards of Fresenius will assess the findings of that investigation," the company said in a statement late on Monday.

  • The Wall Street Journal2 months ago

    [$$] Akorn Shares Plunge as Fresenius Investigates Company

    German health-care company Fresenius said it is looking into possible product development data breaches at Akorn, a probe that could derail its purchase of the U.S. generic drugs manufacturer.

  • Reuters2 months ago

    Fresenius probes Akorn data integrity, questions takeover

    FRANKFURT (Reuters) - German healthcare group Fresenius SE (FREG.DE) on Monday raised doubts about its planned acquisition of Akorn (AKRX.O) because of a probe into data integrity at the U.S. maker of ...

  • Reuters2 months ago

    Fresenius probes Akorn data integrity, questions takeover

    German healthcare group Fresenius SE on Monday raised doubts about its planned acquisition of Akorn because of a probe into data integrity at the U.S. maker of liquid generic drugs. In a statement published after trading hours, Fresenius said it was conducting an independent investigation into "alleged breaches" of data integrity requirements relating to product development at Akorn. "The Management and Supervisory Boards of Fresenius will assess the findings of that investigation," Fresenius said.

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 2. Over the last one-month, outflows of investor capital in ETFs holding AKRX totaled $4.39 billion.

  • Reuters4 months ago

    Fresenius now sees completion of Akorn takeover in early 2018

    Fresenius now expects its planned takeover of Akorn, a U.S. maker of liquid generic drugs, to be completed in early 2018 rather than this year, a spokesman for Fresenius said on Tuesday. "While we've been focused on a 2017 close, it's now clear that closing in early 2018 is more likely, and we're quite comfortable with this timeline," the spokesman said.

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markit4 months ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on December 6. Index (PMI) data, output in the Healthcare sector is rising.

  • Akorn, Inc. breached its 50 day moving average in a Bearish Manner : AKRX-US : November 22, 2017
    Capital Cube5 months ago

    Akorn, Inc. breached its 50 day moving average in a Bearish Manner : AKRX-US : November 22, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Akorn, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)

  • Reuters5 months ago

    Fresenius says Akorn deal closure could take until next year

    German healthcare group Fresenius SE (FREG.DE) said the planned takeover of Akorn (AKRX.O), a U.S. maker of liquid generic drugs, might not be completed before next year as the U.S. antitrust review could take longer than expected. Akorn's business has deteriorated since Fresenius struck the acquisition agreement in April, valuing the maker of medical creams, ophthalmic drugs and oral liquids at $4.75 billion (3.6 billion pounds). Akorn's operating income has slumped on supply disruptions and competition for a range of drugs.